RMS partners with M42 to enhance heart and lung transplant services
As part of an official visit to the United Arab Emirates, a delegation from Bahrain's Royal Medical Services (RMS), led by Brigadier General Dr. Shaikh Fahad bin Khalifa bin Salman Al Khalifa, Commander of the RMS, attended the 50th edition of the Arab Health Conference and Exhibition.
During the visit, RMS signed a partnership with M42, a leading healthcare company, to facilitate heart and lung transplants for patients in Bahrain, ensuring adherence to top international standards.
As part of this collaboration, RMS signed its first memorandum of understanding (MoU) with M42 to support heart and lung transplants in alignment with Abu Dhabi's national organ donation and transplantation programme, Hayat. The MoU was signed during a meeting at Arab Health by Brig. Gen. Dr. Shaikh Fahad bin Khalifa and Hasan Jassim Al Nowais, Managing Director and Group CEO of M42 and Chairman of Cleveland Clinic Abu Dhabi.
Under the agreement, Cleveland Clinic Abu Dhabi, part of M42, will provide specialised transplant services through its Organ Transplant Centre, the UAE's only multi-organ transplant facility. Since its establishment in 2017, the centre has performed over 664 transplants, including 311 in the first half of this year. It has also been recognised by the Department of Health – Abu Dhabi as a centre of excellence for adult cardiac surgery.
This partnership will enable Bahraini patients to benefit from RMS's advanced medical capabilities alongside Cleveland Clinic Abu Dhabi's expertise in heart and lung transplantation.
The strategic partnership between RMS and M42 aims to enhance medical excellence through high-quality education, knowledge exchange, and fellowship programmes. It also focuses on advanced laboratory diagnostics, including genomics, joint research, and improving clinical care in complex medical fields.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
4 days ago
- Daily Tribune
Farah Abdelaal proposes platform linking movies and medicine
TDT | Manama A groundbreaking PhD study by a Bahraini researcher is proposing an unexpected but potentially powerful alliance between the pharmaceutical and film industries. Farah Abdelaal, a PhD candidate in Innovation Management at the Arabian Gulf University, has developed a firstof-its-kind business model and digital platform to unite the two sectors. Her dissertation offers a qualitative framework that aims to revolutionise how medical content is communicated and financed. Health Meets Storytelling The platform concept, still in prototype stage, envisions using cinematic storytelling to disseminate critical health information, raise awareness of conditions like neurological disorders, and even influence public behaviour. 'Films have the ability to reach hearts and minds,' her research notes, adding that blending narrative power with scientific insight can make complex medical issues more relatable and actionable. AI and Neuro-Medicine The study draws from innovation theory, artificial intelligence, business modelling, and neuro-medicine to argue that merging these fields can benefit not just patient education but also pharmaceutical companies seeking sustainable, socially impactful ways to engage with the public. Abdelaal's model also outlines a revenue-sharing mechanism to make such collaborations financially viable for both industries. The research is part of a growing trend that views cross-sector innovation as essential to tackling modern challenges. Her work adds to the region's growing contribution to global discussions around digital health, creative industries, and the evolving role of AI in medicine.
Daily Tribune
4 days ago
- Daily Tribune
Global Icons, Shared Vision: Bahrain Welcomes Olympic Hockey Legend Moritz Fürste
HH Shaikh Nasser and Fürste explore a new frontier of fitness with HYROX collaboration in the Kingdom. Sporting Minds Aligned When elite athletes from different worlds meet—not on the field, but across a table—it often signals something more than polite diplomacy. This week in Bahrain, that meeting took place between His Highness Shaikh Nasser bin Hamad Al Khalifa and Olympic hockey great Moritz Fürste, a two-time gold medalist and the force behind the fast-growing global fitness competition, HYROX. Fürste is building something uniquely powerful with HYROX, blending functional fitness with competitive structure in a way that could reshape how elite and everyday athleticism is approached. And Bahrain, increasingly, is becoming the proving ground for such innovation. Champion Meets a Kingdom on the Rise Fürste's career speaks for itself having secured gold in Beijing 2008, gold again in London 2012, and a bronze in Rio 2016. Few athletes carry such a résumé, and fewer still translate it into entrepreneurial impact as he has with HYROX. His visit to Bahrain was more than ceremonial; it was exploratory, collaborative, and rich with potential. Shaikh Nasser, Bahrain's leading figure in sport and youth development, welcomed Fürste at a time when the Kingdom is amplifying its efforts in endurance and strength-based disciplines. Their discussions touched not only on HYROX but on a broader sporting vision, where resilience meets performance, and fitness becomes a platform for national identity. A Natural Fit Bahrain has already made a name for itself in strength sports through local initiatives like the Strongest Bahraini and Strongest Gulf competitions. HYROX, with its hybrid structure combining distance running and functional strength exercises such as sled pushes and weighted lunges, aligns seamlessly with Bahrain's evolving sporting identity. It's demanding, measurable, and accessible—traits that echo the values instilled by Shaikh Nasser's leadership in the country's athletic programs. A Moment Bigger Than Sport Fürste, in turn, expressed admiration for Bahrain's hospitality and for Shaikh Nasser's role in inspiring a new generation of Bahraini athletes. His acknowledgment underlined a mutual respect—one that extends beyond accolades into shared purpose. The tone of the meeting was visionary as much as it was transactional. With HYROX eyeing international expansion, Bahrain emerges as a compelling partner.
Trade Arabia
5 days ago
- Trade Arabia
M42, partners launch liquid biopsy testing in UAE
M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionise health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA Genetics to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS, powered with SOPHiA DDM technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared:"At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.'
